Phase II Trial of Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-Related Oropharynx Cancer
Latest Information Update: 06 Sep 2024
At a glance
- Drugs Carboplatin (Primary) ; Nivolumab (Primary) ; Paclitaxel (Primary)
- Indications Human papillomavirus infections; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 02 Sep 2024 Status changed from active, no longer recruiting to completed.
- 20 Dec 2022 Status changed from recruiting to active, no longer recruiting.
- 29 Jul 2020 Status changed from suspended to recruiting.